To achieve this, key pathways are blocked/activated by pharmacological means, such as the P2X4-BDNF-KCC2 pathway (Ferrini et al., 2013; Romeo-Guitart and Casas, 2020), BDNF-trkb (Miletic and Miletic, 2008; Rivera et al., 2002; Rivera et al., 2004; Huang et al., 2017; Wenner, 2014; Sánchez-Brualla et al., 2018) or direct regulation of KCC2 activity, such as N and C termin (Ferrini et al., 2013) N-terminal loop Chi et al., 2021, phosphorylation of serine 940 (Leonzino et al., 2016) will likely be potential targets for clinical treatment of spinal cord injury and its complications. The gene discussed is P2RX4; the disease is spinal cord injury.